Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 877 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Endocrine Clear all

Conditions: Hemorrhagic Shock
Interventions: Premarin IV, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 1, Noncompliance, Patient
Interventions: Continuous Glucose Monitoring, Secure texting; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 13 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: Lapatinib, Trastuzumab, Endocrine; Drug
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Breast Cancer Risk
Interventions: Breast Cancer Risk Reduction Household Intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 65 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Breast Tumors, Metastatic Cancer
Interventions: AMG 479, Placebo; Drug
Lead sponsor: NantCell, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 25
States / cities: Chandler, Arizona • Anaheim, California • Beverly Hills, California + 22 more

Conditions: Breast Cancer
Interventions: Lapatinib, Letrozole, Trastuzumab; Drug
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Pancreatic Islets of Langerhans Cell Transplant; Procedure
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type1 Diabetes Mellitus
Interventions: Continuous Glucose Monitor (CGM)+Decision Support System (DSS), Continuous Glucose Monitor (CGM) alone; Device · Other
Lead sponsor: University of Virginia; Other
Eligibility: 15 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Stanford, California • New York, New York • Charlottesville, Virginia

Conditions: Metastatic Breast Cancer
Interventions: Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Gilbert, Arizona • Burbank, California • Corona, California + 17 more

Conditions: fMRI
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 7 Years to 35 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Adherence, Medication, Side Effect
Interventions: BETA-Text text messaging intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Growth Hormone Deficiency, Septo-Optic Dysplasia, Hypopituitarism
Interventions: Nutropin AQ; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 5 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Cancer of the Breast
Interventions: DiviTum® TKa assay, Study Care Plans; Device · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Inavolisib, Placebo, CDK4/6i, Letrozole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 62
States / cities: Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 50 more

Conditions: Non Functioning Entero-pancreatic Endocrine Tumour
Interventions: lanreotide (Autogel formulation); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Endocrine Therapy and a CDK 4/6 inhibitor; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Pain, Pain, Chronic, Pain Syndrome, Pain, Neuropathic, Pain, Intractable
Interventions: Mindfulness Based Intervention; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hormone-sensitive Metastatic Breast Cancer
Interventions: OSI-906, Erlotinib, Letrozole, Goserelin; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Franklin, Tennessee • Nashville, Tennessee

Conditions: Elderly
Interventions: Fluid Supplement, Solid Supplement; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 60 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Insulin Resistance, Obesity
Interventions: Roux-en-Y Gastric Bypass (RYGBP), Sleeve Gastrectomy (SG), Very Low Calorie Diet (VLCD); Procedure · Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Hyperparathyroidism
Interventions: Ultrasound-Guided Parathyroid Nanosecond Pulsed Field Ablation (nsPFA); Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Low Grade Ovarian Serous Adenocarcinoma
Interventions: nab-Sirolimus, Fulvestrant; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Type 2 Diabetes Mellitus
Interventions: Diabetes Medication Choice Cards; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 6
States / cities: Albert Lea, Minnesota • Kasson, Minnesota • Mankato, Minnesota + 3 more

Conditions: Type 2 Diabetes
Interventions: Enhanced Telemedicine for Type 2 Diabetes, Usual Telemedicine Endocrinology Care for T2D; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)

Feasibility and Effectiveness of Real-time, Remote Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes

Lapatinib and Trastuzumab With or Without Endocrine Therapy

Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

UVA Islet Cell Transplantation in Patients With Type I Diabetes

Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty

Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Investigating Biological Targets, Markers, and Intervention for Chronic Pain

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

The Body's Response to Food Intake in Older Adults

Metabolism and Bariatric Surgery Study

Treating PHPT With the nPulse™ Vybrance™ PE System

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication

Enhancing Telemedicine for T2D